

1 **Antibiotic prescriptions in children with COVID-19 and Multisystem Inflammatory**  
2 **Syndrome: a multinational experience in 990 cases from Latin America**

3 Adriana Yock-Corrales, MD<sup>1</sup>; Jacopo Lenzi, PhD<sup>2</sup>; Rolando Ulloa-Gutiérrez, MD<sup>3</sup>; Jessica Gómez-  
4 Vargas, MD<sup>1</sup>; Antúnez-Montes Omar Yassef MD<sup>4</sup>; Jorge Alberto Rios Aida MD<sup>5</sup>; Olguita del  
5 Aguila, MD<sup>6</sup>; Erick Arteaga-Menchaca MD<sup>7</sup>; Francisco Campos MD<sup>8</sup>; Fadia Uribe MD<sup>8</sup>; Andrea  
6 Parra Buitrago, MD<sup>9,10</sup>; Lina Maria Betancur Londoño, MD<sup>9</sup>; Martin Brizuela MD<sup>11</sup>; Danilo  
7 Buonsenso MD<sup>12,13,14</sup>

8

9 <sup>1</sup> Pediatric Emergency Department, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS,  
10 San José, Costa Rica.

11 <sup>2</sup> Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of  
12 Bologna, Bologna, Italy

13 <sup>3</sup> Infectious Disease Department. Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS,  
14 San José, Costa Rica.

15 <sup>4</sup> Departamento de Docencia e Investigación, Instituto Latinoamericano de Ecografía en Medicina  
16 (ILEM)., Ciudad de Mexico, Mexico

17 <sup>5</sup> CLÍNICA JAS MÉDICA, Lima, Perú

18 <sup>6</sup> Unidad de Infectología Pediátrica del Hospital Nacional Edgardo Rebagliati Martins-Lima-Perú.

19 <sup>7</sup> Hospital General Regional 200 IMSS, Mexico

20 <sup>8</sup> Hospital Madre Niño San Bartolome, Lima, Peru

21 <sup>9</sup> Hospital Pablo Tobon Uribe Medellin, Colombia

22 <sup>10</sup> Fundacion Neumologica Colombiana, Bogotá, Colombia

23 <sup>11</sup> Pediatric Infectious Disease, Hospital isidoro Iriarte, Quilmes, Buenos Aires, Argentina

24 <sup>12</sup> Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario  
25 A. Gemelli, Rome, Italy

26 <sup>13</sup> Dipartimento di Scienze Biotechnologiche di Base, Cliniche Intensivologiche e Perioperatorie,  
27 Università Cattolica del Sacro Cuore, Rome, Italy

28 <sup>14</sup>Global Health Research Institute, Istituto di Igiene, Università Cattolica del Sacro Cuore, Roma,  
29 Italia

30 **Email addresses:**

31 Adriana Yock-Corrales, [adriyock@gmail.com](mailto:adriyock@gmail.com)

32 Jacopo Lenzi, [jacopo.lenzi2@unibo.it](mailto:jacopo.lenzi2@unibo.it)

33 Rolando Ulloa-Gutiérrez, [rolandoug@gmail.com](mailto:rolandoug@gmail.com)

34 Jessica Gómez-Vargas, [jemagova@gmail.com](mailto:jemagova@gmail.com)

35 Antúnez-Montes Omar Yassef, [antunezyassef@gmail.com](mailto:antunezyassef@gmail.com)

36 Jorge Alberto Rios Aida, [jriosaida@gmail.com](mailto:jriosaida@gmail.com)

37 Olguita del Aguila, [odaguila@hotmail.com](mailto:odaguila@hotmail.com)

38 Erick Arteaga-Menchaca, [docarteaga@hotmail.com](mailto:docarteaga@hotmail.com)

39 Francisco Campos, [francisco.e.campos@gmail.com](mailto:francisco.e.campos@gmail.com)

40 Fadia Uribe, [kafaur87@hotmail.com](mailto:kafaur87@hotmail.com)

41 Andrea Parra Buitrago, [aparra@neumologica.org](mailto:aparra@neumologica.org)

42 Lina Maria Betancur Londoño, [lina\\_b16@yahoo.com](mailto:lina_b16@yahoo.com)

43 Martin Brizuela, [martin.brizuela1984@gmail.com](mailto:martin.brizuela1984@gmail.com)

44 Danilo Buonsenso, [danilobuonsenso@gmail.com](mailto:danilobuonsenso@gmail.com)

45

46 **Abstract**

47 **Background**

48 To date, there are no comprehensive data on antibiotic use in children with COVID-19 and  
49 Multisystem Inflammatory Syndrome (MIS-C).

50 **Methods**

51 Multicenter cohort study from 5 Latin American countries. Children 17 years of age or younger  
52 with microbiologically confirmed SARS-CoV-2 infection or fulfilling MIS-C definition were  
53 included. Antibiotic prescriptions were collected and factors associated with their use were  
54 calculated.

55 **Findings**

56 990 children were included, with a median age of 3 years (interquartile range 1–9). Of these, 69  
57 (7.0%) were diagnosed with MIS-C. The prevalence of antibiotic use was 24.5% ( $n = 243$ ). MIS-C  
58 with (OR = 45.48) or without (OR = 10.35) cardiac involvement, provision of intensive care (OR  
59 = 9.60), need for hospital care (OR = 6.87), pneumonia and/or ARDS detected through chest X-  
60 rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support,  
61 mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50)  
62 were independently associated with increased use of antibiotics. On the contrary, lower  
63 respiratory tract infections without radiologic evidence of pneumonia/ARDS and not requiring  
64 respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics.  
65 There was significant variation in antibiotic use across the hospitals.

66 **Conclusions**

67 Our study showed a relatively high rate of antibiotic prescriptions in children with COVID-19 and  
68 in particular in those with severe disease or MIS-C. Importantly, we found a significant variation in  
69 reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices,  
70 highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in  
71 children with COVID-19. Prospective studies are needed to provide better evidence on the  
72 recognition and management of bacterial infections in COVID-19 children.

73

74

75

76

77

78 **Key Words:**

79 COVID-19 ; SARS-CoV-2 ; MIS-C ; antibiotic stewardship

80 **List of Abbreviation**

81 COVID-19 : coronavirus disease 2019

82 SARS-CoV-2 : severe acute respiratory syndrome coronavirus-2

83 MIS-C : multisystem inflammatory syndrome in children

84

85 **What is known**

86 COVID-19 may worsen antibiotic prescription practices

87 **What this new**

88 COVID-19 and MIS-C children frequently received antibiotics

89 There was a wide variation in antibiotic prescriptions among institutions, highlighting the lack of  
90 practice guidelines in the use of antibiotics in children with COVID-19

91

92

93

94

95

96

97

98

99

100

101 **\*Declarations**

102 **Funding:** no funds received

103 **Conflicts of interest:** nothing to declare

104 **Ethics approval:** Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-

105 06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020

106 **Consent to participate:** approved

107 **Consent for publication:** approved

108 **Availability of data and material:** available upon request

109 **Authors' contributions:** DB conceptualized the study. JL performed statistical analyses. All authors

110 contributed with data collection, writing of the draft of the manuscript- All authors read and approved the

111 final version of the manuscript.

112

113

114

115

## 116 **Introduction**

117 Months after the first description of COVID-19 in China, growing evidence is raising about the  
118 impact of SARS-CoV-2 infection on the pediatric population. Several studies from China (1),  
119 Europe (2,3), United States (4) and Latin America (5) are clarifying that COVID-19 in children is  
120 typically mild, although patients with medically complex conditions or those of minority  
121 race/ethnicity deserve more attention because they may be at risk of more severe disease (4).

122 The Multisystem Inflammatory Syndrome (MIS-C), an entity not yet fully clarified related to  
123 SARS-CoV-2, is a severe complication of the exposition to the virus, which may require Intensive  
124 Care Admission, mechanical ventilation and cardio-respiratory support, rarely leading to death (6).

125 Because SARS-CoV-2 is a viral infection, and the resulting disease is usually mild in children, it is  
126 not expected that a child with COVID-19 would routinely receive antimicrobials. This is  
127 particularly true for the second period of the pandemic, when the non-utility of azithromycin,  
128 initially suggested as a drug with potential anti-viral properties (7), has been showed (8). The MIS-  
129 C can be an exception to this concept, since the severe and acute presentation may be similar to the  
130 toxic-shock syndrome and available consensus documents suggest empiric wide-spectrum antibiotic  
131 therapy until bacterial infections are ruled-out (9).

132 Nevertheless, there are growing concerns about the possible negative impact of the pandemic on  
133 antimicrobial use. While this is particularly discussed for adults with COVID-19 (10), Velasco-  
134 Arnaiz et al (11) reported preliminary data suggesting that the pandemic has the potential to have a  
135 significant impact on antimicrobial use in the pediatric inpatient population. They did assess  
136 antibiotic prescriptions during and before the pandemic, but did not assess directly antibiotic use  
137 and its determinants in COVID-19 children.

138 Since cases are constantly raising worldwide, it is expected that SARS-CoV-2 will circulate still for  
139 a long time, therefore the appropriate management of children with COVID-19 is a priority. While  
140 the pandemic only determined a limited direct impact on children, inappropriate prescriptions have  
141 the potential of worsening an already dangerous situation, i.e. antimicrobial resistance.

142 Due to the gap in available literature, we performed a multinational study in Latin America aiming  
143 to assess the use of antibiotics in children with COVID-19 and understand the determinants of its  
144 use.

145

## 146 **MATERIALS AND METHODS**

### 147 *Study Design and Participants*

148 This study is part of an ongoing independent project assessing COVID-19 and MIS-C in Latin  
149 American children, already presented elsewhere (12) and with a previous published paper  
150 describing an initial group of 409 children with confirmed COVID-19 (5). For the current study, we  
151 aimed to assess determinants of antibiotic use in children with COVID-19. We implemented the  
152 previously used dataset (2, 5) including data regarding name of antibiotic used and the reason why  
153 the attending clinician decided to administer antibiotics. The remaining variables are those  
154 previously used and included age, gender, symptoms, imaging, underlying medical conditions, need  
155 for hospital and NICU/PICU admission, respiratory and cardiovascular support, other viral co-  
156 infections, drugs used to treat COVID-19, development of MIS-C and type of organ involvement,  
157 and outcome.

158 The study was reviewed and approved by the CoviD in sOuth aMerIcaN children—study GrOup  
159 core group and approved by the Ethics Committee of the coordinating center and by each  
160 participating center (Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-  
161 FT-06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020). The study was  
162 conducted in accordance with the Declaration of Helsinki and its amendments. No personal or  
163 identifiable data were collected during the conduct of this study.

### 164 *Statistical analysis*

165 Summary statistics for the study sample were presented as counts and percentages. The  
166 association of relevant demographic and clinical characteristics with antibiotic use was assessed  
167 using a multivariable logistic regression model; the effect size of covariates was expressed by

168 odds ratios (ORs) with 95% confidence intervals (CIs). The variables considered in this analysis  
169 were age, sex, medical history of immunodeficiency, immunosuppressants or chemotherapy,  
170 hospital care, pyrexia, upper and lower respiratory tract infections, gastrointestinal symptoms,  
171 headache, chest X-ray abnormalities, respiratory support, administration of systemic  
172 corticosteroids, and diagnosis of MIS-C, both with and without cardiac involvement. A set of  
173 dummy variables for individual hospitals was also included in the model to adjust for the  
174 potential bias of confounding by center. All data were analyzed using the Stata 15 software  
175 (StataCorp. 2017. *Stata Statistical Software: Release 15*. College Station, TX: StataCorp LLC). The  
176 significance level was set at 5% and all tests were 2-sided.

### 177 ***Role of the Funding Source***

178 The study was not supported by any funding. The corresponding authors had full access to all the  
179 data and had the final responsibility for the decision to submit for publication.

### 180 ***Dataset availability***

181 The dataset generated for this study is available upon request to the corresponding author.

182

## 183 **RESULTS**

### 184 ***Study population***

185 A total of 921 children (93.0%) with microbiologically confirmed COVID-19 and 69 children  
186 (7.0%) with MIS-C from Peru ( $n = 383$ , 38.7%), Costa Rica ( $n = 299$ , 30.2%), Argentina ( $n =$   
187  $253$ , 25.6%), Colombia ( $n = 43$ , 4.3%) and Mexico ( $n = 12$ , 1.2%) were included in the study.

188 The demographic and clinical characteristics of the 990 study patients are summarized in Table 1.

189 The median age was 3 years (interquartile range: 1–9), ranging from 2 days to 17 years; 484  
190 (48.9%) were female. The most common known source of transmission of the infection was a  
191 parent, considered the index case in 281 (28.4%) cases. A total of 303 (30.6%) children were  
192 admitted to hospital and 47 (4.7%) required admission to a Pediatric Intensive Care Unit (PICU).



193 Fever was reported in 677 cases (68.4%); 466 (47.1%) children had symptoms suggestive of upper  
194 respiratory tract infection while 215 (21.7%) had lower respiratory tract symptoms; 301 (30.4%)  
195 had gastrointestinal symptoms. A chest radiograph was done in 285 (28.8%) patients. Of these, 92  
196 (32.3%) had signs of COVID-19 pneumonia. Respiratory co-infections were detected in 14 (1.4%)  
197 children.

198 We found that 118 (11.9%) individuals required respiratory support; 117 (11.8%) required low-flow  
199 oxygen support, 11 (1.1%) were started on continuous positive airway pressure and 31 (3.1%) on  
200 mechanical ventilation. A total of 29 (2.9%) patients required inotropic support. Eight children died  
201 (0.8%). Further details described in table 1.

202

### 203 ***Antibiotic use in COVID-19 and MIS-C children***

204 The prevalence of antibiotic use was 24.5% ( $n = 243$ ). As shown in Figure 1, sepsis was the most  
205 common reason for administering antibiotics (22.6%), followed by pneumonia (13.6%), surgical  
206 causes (11.5%) and upper or mild respiratory infections (9.5%). Information about the classes of  
207 antibiotics used was available for 153 (63.0%) patients. Among these, 86 (56.2%) received  
208 cephalosporines, 33 (21.6%) aminoglycosides, 33 (21.6%) penicillins, 31 (20.3%)  
209 antistaphylococcal drugs, 17 (11.1%) antianaerobic drugs, 14 (9.2%) macrolides, 11 (7.2%)  
210 carbapenems, and 1 (0.7%) fluoroquinolones. The percentage distribution of single and  
211 combination antibiotic therapies is illustrated in Figure 2. The rate of antibiotic prescriptions  
212 remained stable during the whole study period with an average decrease of  $-0.6\%$  (95% CI  $-$   
213  $2.6\%$ ,  $1.3\%$ ) from April 2020 to October 2020 (Figure 3).

214 On multivariable analysis (Table 2), MIS-C with cardiac involvement (OR = 45.48), MIS-C with  
215 no cardiac involvement (OR = 10.35), provision of intensive care (OR = 9.60), need for  
216 hospitalization (OR = 6.87), pneumonia and/or ARDS detected through chest X-rays (OR = 4.40),  
217 administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or  
218 CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) were independently

219 associated with increased use of antibiotics. On the contrary, lower respiratory tract infections not  
220 suggestive of pneumonia/ARDS and not requiring respiratory support (OR = 0.34) were  
221 independently associated with decreased use of antibiotics. We also found large and significant  
222 variations in antibiotic use across the hospitals.

223

## 224 **DISCUSSION**

225 In our study, the prevalence of antibiotic prescribing in children with COVID-19 and MIS-C was  
226 24.5%. We found significant variations in classes of antibiotics used and even large differences  
227 across the hospitals. The rate of antibiotic prescriptions was significantly higher in children with  
228 MIS-C, those requiring respiratory support, those with radiologic evidence of pneumonia/ARDS  
229 and those with fever. Interestingly, younger children and those with symptoms suggestive of  
230 lower respiratory tract infections without radiologic evidence of pneumonia/ARDS and not  
231 requiring respiratory support were less frequently prescribed with antibiotics. Importantly, also  
232 the only need for admission to the hospital was associated with a higher rate of antibiotic  
233 prescription. To our knowledge, this is the first multinational study assessing the use of antibiotics  
234 in children with COVID-19 and MIS-C, therefore pediatric studies to compare our findings are not  
235 available.

236 Velasco-Arnaiz et al (11) are the only authors that evaluated antibiotic use in a pediatric referral  
237 center before and during the pandemic. The use of azithromycin, initially considered as first-line  
238 therapy in severe COVID-19 patients in combination with hydroxychloroquine, increased,  
239 particularly in PICU setting. The use of ceftriaxone and teicoplanin, doubled in the PICU in April  
240 2020 compared with April 2019. In non-PICU patients, piperacillin-tazobactam and ciprofloxacin  
241 use increased. Other antibiotics for community-acquired infections were prescribed less than in the  
242 same period in 2019, and cefazolin use decreased due to the dramatic drop in the number of  
243 surgeries. Also in our cohort, cephalosporins were frequently prescribed, while, interestingly,

244 macrolides represented only 9.2% of all prescriptions. This is probably because the peak of  
245 pediatric cases in Latin America was registered when the concept of utility of azythromicine in  
246 COVID-19 was weaker.

247 Confirmed or suspected sepsis was the main reason for antibiotic prescription. This was an expected  
248 finding, since the pathogenesis (13) and clinical presentation of MIS-C overlap with those of sepsis,  
249 and there is general consensus for starting broad-spectrum antibiotics in these children (9).  
250 However, MIS-C children represented only 7.0% of the entire cohort, while 24.5% of children  
251 received antibiotics. These data suggest a potential overuse of empirical antibiotics in COVID-19  
252 children. Considering that COVID-19 is often a milder disease in children compared with adults  
253 (14), the pediatric community is expected to empirically use antibiotics less frequently. However,  
254 the rate of prescriptions we detected is not widely different from those reported in adult studies. In  
255 fact, in our study, the need for hospital admission was independently associated with a higher  
256 probability of receiving antibiotic (OR 6.87, 95% CI 4.34-10.89). Addressing adult studies, Seatone  
257 et al reported that 38.3% of COVID-19 patients were prescribed antibiotics. Antibiotic prevalence  
258 was 45.0%, and 73.9% were prescribed for suspected respiratory tract infection. Amoxicillin,  
259 doxycycline and co-amoxiclav accounted for over half of all antibiotics in non-critical care wards,  
260 and meropenem, piperacillin-tazobactam and co-amoxiclav accounted for approximately half  
261 prescribed in critical care (15).

262 Although there are no data on bacterial co-infections in children with COVID-19 that may inform  
263 better policies of pediatric antimicrobial stewardships during the pandemic, even in adults, where  
264 COVID-19 is having a much more severe impact, the burden of bacterial co-infections seems to be  
265 relatively low in most published studies (16-23). Buehrle et al found bacterial infections in 31%  
266 (5/16) of COVID-19 patients, while antibiotics were administered to 56% (9/16) of patients during  
267 hospitalization, but 100% (9/9) of patients requiring ICU care (16). In Spain, Garcia-Vidal et al (17)  
268 found that 31/989 (3%) COVID-19 adults presented with community-acquired co-infections,

269 mainly *Streptococcus pneumoniae* and *Staphylococcus aureus* pneumonia. Hospital-acquired  
270 infection was diagnosed in 43/989 patients (4%), with 25/44 (57%) occurring in critical care  
271 (mainly *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella* spp., and *Staphylococcus aureus*).  
272 Coagulase-negative staphylococci were the most common organisms causing documented  
273 bloodstream infection (7/16; 44%). Low observed rates of bacterial and fungal infection in COVID-  
274 19 patients have also been reported from the UK, where Hughes identified bacterial infection in 51/  
275 836 COVID-19 patients (6%) (18, 19). A review of eighteen full texts showed that 62/806 (8%)  
276 COVID-19 patients experienced bacterial/fungal co-infection during hospital admission, while on  
277 secondary analysis, 1450/2010 (72%) of patients were found to have received antimicrobial therapy  
278 (20). One Italian study even saw a reduction in *Clostridioides difficile* infections in hospitalized  
279 patients (21). In a rapid review, Fattorini et al found that only 1.3% of 522 COVID-19 patients in  
280 intensive care units, and apparently no COVID19 patients in other units, developed a healthcare-  
281 associated super-infection with antimicrobial-resistant bacteria (22, 23).

282 In our study, having signs or symptoms suggestive of lower respiratory tract infections, without  
283 radiologic evidence of pneumonia/ARDS, was associated with a lower probability of receiving  
284 antibiotics. This finding may be explained by the fact that in pediatrics such presentations are  
285 usually suggestive of a clinical diagnosis of bronchiolitis, wheezing or asthma, conditions that do  
286 not require routine antibiotic administration.

287 Our study clearly shows a high variability of reasons for antibiotic prescriptions and regimens  
288 chosen, as well as a significant variability among different centers. These findings highlight the  
289 uncertainties that physicians daily face in the management of COVID-19 patients. While the World  
290 Health Organization currently recommends against the prescribing of antimicrobials in mild to  
291 moderate COVID-19 cases without clear indication of bacterial infection (24), the difficulty in  
292 differentiating COVID-19 from bacterial infections on initial presentation challenges clinicians and  
293 antimicrobial stewardship practices (25). Almost after one year of the pandemic, there is no

294 evidence to support decision-making on bacterial infection and antimicrobial stewardship in the  
295 context of COVID-19 (19), particularly in children. This uncertainty is likely to drive unnecessary  
296 antimicrobial prescribing in COVID-19 children who are unlikely, according to adult evidences, to  
297 benefit from empiric antibiotic prescriptions. This scenario will potentially increase the selection of  
298 drug resistant infections (26) and will make patients more vulnerable to bacterial infections, even  
299 during future viral pandemics that may favor bacterial co-infections from drug resistant bugs (27).

300 Our study has some limitations to address. We did not collect bacteria isolation and antibiotic  
301 sensitivities throughout the pandemic in the participating centers. Blood results, including  
302 inflammatory markers, were not collected. In addition, an independent expert did not assess the  
303 appropriateness of antibiotic prescription, nor the length of administration. Last, the reason for  
304 starting antibiotic was subjectively based on the evaluating clinician. The main reason for this  
305 approach was that Latin American clinicians are still struggling in the front-line, with hospitals  
306 having limited human resources to dedicate extra time for clinical research. Despite these  
307 limitations, this study provides the largest overview of antibiotic use in children with COVID-19  
308 and MIS-C to date.

309 In conclusion, our study showed a relatively high rate of antibiotic prescriptions in children with  
310 COVID-19 and in particular in those with severe disease or MIS-C. Importantly, we found a  
311 significant variation in reasons for prescriptions of antibiotics and type of chosen therapies, as well  
312 in hospital practices, highlighting current uncertainties and lack of guidelines for the recognition of  
313 bacterial infections in COVID-19 children. Prospective studies are urgently needed to provide better  
314 evidence on the recognition and management of bacterial infections in COVID-19 children, as well  
315 as to develop dedicated antimicrobial stewardship programs.

316

317

318 **ACKNOWLEDGMENTS**

319 We are grateful to all collaborators that helped the development of the DOMINGO study group.

320

## 321 **References**

- 322 1- Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children  
323 in China. *Pediatrics*. 2020 Jun;145(6):e20200702. doi: 10.1542/peds.2020-0702.
- 324 2- Götzinger F, Santiago-García B, Noguera-Julián A, Lanasma M, Lancella L, Calò Carducci FI,  
325 Gabrovská N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, Shingadia D, Soriano-  
326 Arandes A, Melendo S, Lanari M, Pierantoni L, Wagner N, L'Huillier AG, Heiningen U, Ritz N,  
327 Bandi S, Krajcar N, Roglič S, Santos M, Christiaens C, Creuven M, Buonsenso D, Welch SB, Bogyi  
328 M, Brinkmann F, Tebruegge M; ptbnet COVID-19 Study Group. COVID-19 in children and  
329 adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*. 2020  
330 Sep;4(9):653-661. doi: 10.1016/S2352-4642(20)30177-2.
- 331 3- Parri N, Lenge M, Cantoni B, Arrighini A, Romanengo M, Urbino A, Da Dalt L, Verdoni L,  
332 Giacchero R, Lanari M, Musolino AM, Biban P, La Fauci G, Pilotto C, Buonsenso D, Chiossi M,  
333 Agostiniani R, Plebani A, Zampogna S, Barbieri MA, De Masi S, Agostoni C, Masi S;  
334 CONFIDENCE RESEARCH GROUP. COVID-19 in 17 Italian Pediatric Emergency Departments.  
335 *Pediatrics*. 2020 Sep 23:e20201235. doi: 10.1542/peds.2020-1235.
- 336 4- Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, Eckrich D,  
337 Kitzmiller M, Lin SM, Magnusen BC, Newland J, Pajor NM, Ranade D, Rao S, Sofela O, Zahner J,  
338 Bruno C, Forrest CB. Assessment of 135□794 Pediatric Patients Tested for Severe Acute  
339 Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA Pediatr*. 2020 Nov 23. doi:  
340 10.1001/jamapediatrics.2020.5052.
- 341 5- Antúnez-Montes OY, Escamilla MI, Figueroa-Urbe AF, Arteaga-Menchaca E, Lavariega-Saráchaga  
342 M, Salcedo-Lozada P, Melchior P, de Oliveira RB, Tirado Caballero JC, Redondo HP, Montes  
343 Fontalvo LV, Hernandez R, Chavez C, Campos F, Uribe F, Del Aguila O, Rios Aida JA, Buitrago  
344 AP, Betancur Londoño LM, Mendoza Vega LF, Hernández CA, Sali M, Higuera Palacio JE, Gomez-  
345 Vargas J, Yock-Corrales A, Buonsenso D. COVID-19 and Multisystem Inflammatory Syndrome in

- 346 Latin American Children: A Multinational Study. *Pediatr Infect Dis J*. 2020 Oct 12. doi:  
347 10.1097/INF.0000000000002949.
- 348 6- Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller  
349 O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A, Shimizu C, Herberg J,  
350 Burns JC, Lyall H, Levin M; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia.  
351 Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome  
352 Temporally Associated With SARS-CoV-2. *JAMA*. 2020 Jul 21;324(3):259-269. doi:  
353 10.1001/jama.2020.10369.
- 354 7- Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the  
355 Antiviral Activity of Azithromycin and Use in COVID-19. *Clin Pharmacol Ther*. 2020  
356 Aug;108(2):201-211. doi: 10.1002/cpt.1857.
- 357 8- Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP,  
358 Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramuja L,  
359 Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE,  
360 Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR,  
361 Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD,  
362 Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or  
363 without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020 Nov 19;383(21):2041-  
364 2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23. Erratum in: *N Engl J Med*. 2020 Nov  
365 19;383(21):e119.
- 366 9- Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, Kaleem M, Tulloh R,  
367 Peters MJ, Almond S, Davis PJ, Levin M, Tometzki A, Faust SN, Knight M, Kenny S; PIMS-TS  
368 National Consensus Management Study Group. A national consensus management pathway for  
369 paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS):  
370 results of a national Delphi process. *Lancet Child Adolesc Health*. 2020 Sep 18:S2352-  
371 4642(20)30304-7. doi: 10.1016/S2352-4642(20)30304-7.
- 372 10- Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, Nguyen MH, Clancy  
373 CJ. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease

- 374 2019 Epicenter. *Antimicrob Agents Chemother.* 2020 Oct 20;64(11):e01011-20. doi:  
375 10.1128/AAC.01011-20.
- 376 11- Velasco-Arnaiz E, López-Ramos MG, Simó-Nebot S, Jordan I, Ríos-Barnés M, Urrea-Ayala M,  
377 Monsonís M, Fortuny C, Noguera-Julian A; Kids Corona project. Pediatric antimicrobial  
378 stewardship in the COVID-19 outbreak. *Infect Control Hosp Epidemiol.* 2020 Jun 24:1-3. doi:  
379 10.1017/ice.2020.312. Epub ahead of print.
- 380 12- Antúñez-Montes OY, Escamilla MI, Figueroa-Urbe AF, Arteaga-Menchaca E, Lavariega-Sárrachaga  
381 M, Salcedo-Lozada P, Sunohara RA, Melchior P, Del Razo JOF, Tirado-Caballero JC, Tasayco-  
382 Muñoz JA, Pinzon-Redondo H, Montes-Fontalvo LV, Ochoa T, Eduardo Campos F, Hernandez R,  
383 Limansky L, Del Aguila O, Buonsenso D. COVID-19 in South American Children: A Call For  
384 Action. *Pediatr Infect Dis J.* 2020 Oct;39(10):e332-e334. doi: 10.1097/INF.0000000000002851.
- 385 13- Buonsenso D, Riitano F, Valentini P. Pediatric Inflammatory Multisystem Syndrome Temporally  
386 Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic  
387 Shock Syndrome. *Front Pediatr.* 2020 Sep 11;8:574. doi: 10.3389/fped.2020.00574.
- 388 14- Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among Children  
389 and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatr.*  
390 Sep 2020;doi:10.1001/jamapediatrics.2020.4573
- 391 15- Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, Griffith D, Jeffreys D,  
392 Hamilton K, Choo-Kang B, Brittain S, Guthrie D, Sneddon J. Survey of antibiotic and antifungal  
393 prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. *J Infect.* 2020  
394 Sep 26:S0163-4453(20)30616-2. doi: 10.1016/j.jinf.2020.09.024.
- 395 16- Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, Nguyen MH, Clancy  
396 CJ. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease  
397 2019 Epicenter. *Antimicrob Agents Chemother.* 2020 Oct 20;64(11):e01011-20. doi:  
398 10.1128/AAC.01011-20.
- 399 17- Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M,  
400 Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grafia I, Meira F,  
401 Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, García F, Mensa J, Martínez JA,



- 402 Soriano A; COVID-19 Researchers Group. Incidence of co-infections and superinfections in  
403 hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect.* 2020 Jul  
404 31:S1198-743X(20)30450-X. doi: 10.1016/j.cmi.2020.07.041.
- 405 18- Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among  
406 hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.  
407 *Clin Microbiol Infect.* 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025.
- 408 19- Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in  
409 COVID-19. *Clin Microbiol Infect.* 2020 Oct 9:S1198-743X(20)30577-2. doi:  
410 10.1016/j.cmi.2020.09.025.
- 411 20- Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G,  
412 Holmes A. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to  
413 support COVID-19 antimicrobial prescribing. *Clin Infect Dis.* 2020 May 2:ciaa530. doi:  
414 10.1093/cid/ciaa530.
- 415 21- Bentivegna E, Alessio G, Spuntarelli V, Luciani M, Santino I, Simmaco M, et al. Impact of COVID-  
416 19 prevention measures on risk of health care-associated *Clostridium difficile* infection. *Am J Infect*  
417 *Control.* 2020 Oct 5;S0196-6553(20)30891-9. <https://doi.org/10.1016/j.ajic.2020.09.010>
- 418 22- Fattorini L, Creti R, Palma C, Pantosti A, Unit of Antibiotic Resistance and Special Pathogens, Unit  
419 of Antibiotic Resistance and Special Pathogens of the Department of Infectious Diseases, Istituto  
420 Superiore di Sanità, Rome. Bacterial coinfections in COVID-19: an underestimated adversary. *Ann*  
421 *Ist Super Sanita.* 2020;56(3):359-64. [https://doi.org/10.4415/ANN\\_20\\_03\\_14](https://doi.org/10.4415/ANN_20_03_14)
- 422 23- Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial  
423 resistance? *Euro Surveill.* 2020 Nov;25(45):2001886. doi: 10.2807/1560-  
424 7917.ES.2020.25.45.2001886.
- 425 24- World Health Organization. Clinical management of COVID-19. 2020.  
426 <https://www.who.int/publications/i/item/clinical-management-of-covid-19>.
- 427 25- Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial  
428 stewardship principles! *Clin Microbiol Infect* 2020;26: 808e10.  
429 <https://doi.org/10.1016/j.cmi.2020.04.024>.

430 26- Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the  
 431 mechanisms and drivers of antimicrobial resistance. *Lancet* 2016;387:176e87.  
 432 [https://doi.org/10.1016/S0140-6736\(15\)00473-0](https://doi.org/10.1016/S0140-6736(15)00473-0).

433 **27-** Vaillancourt M, Jorth P. The Unrecognized Threat of Secondary Bacterial Infections with COVID-  
 434 19. *mBio*. 2020 Aug 7;11(4):e01806-20. doi: 10.1128/mBio.01806-20.

435

436

Characteristic	<i>n</i>	%
Female sex	484	48.9
Age group		
0 y	202	20.4
1–2 y	229	23.1
3–5 y	144	14.5
6–11 y	247	24.9
12–17 y	168	17.0
COVID-19 confirmed by real-time PCR	639	64.5
Positive SARS-CoV-2 IgG	352	35.6
Delay between onset and diagnosis		
0–1 d	437	44.1
2–7 d	460	46.5
>7 d	93	9.4
Likely index case		
Parent	281	28.4
Sibling	14	1.4
Other	120	12.1
Unknown	575	58.1
Medical history		
Known history of BCG vaccine	740	74.7
Pre-existing medical conditions	128	12.9
Immunosuppressants at the time of diagnosis	11	1.1
Primary or secondary immunodeficiency	8	0.8
Chemotherapy over the last 6 months	8	0.8
Admitted to the hospital	303	30.6
Intensive care during hospital stay	47	4.7
Symptoms		
Pyrexia ( $\geq 38.0 \geq 100.4$ °C/°F)	677	68.4
Upper respiratory tract infection	466	47.1
Diarrhea and/or vomiting	301	30.4
Lower respiratory tract infection	215	21.7
Headache	104	10.5
Chest X-ray		
Not performed	705	71.2
Negative	193	19.5
Positive (pneumonia* and/or ARDS†)	92	9.3
Respiratory support		
Oxygen support	117	11.8
Mechanical ventilation	31	3.1

Continuous positive airway pressure (CPAP)	11	1.1
Extracorporeal membrane oxygenation (ECMO)	0	0.0
Administration of inotropes	29	2.9
Co-infections detected in respiratory samples(s)‡	14	1.4
Drug administration		
Systemic corticosteroids	90	9.1
Intravenous immunoglobulin (IVIG)	60	6.1
Hydroxychloroquine	9	0.9
Oseltamivir	8	0.8
Lopinavir or ritonavir	3	0.3
Non-corticosteroid immunosuppressants	3	0.3
Favipiravir	2	0.2
Remdesivir	2	0.2
Chloroquine, ribavirin or zanamivir	0	0.0
MIS-C diagnosis		
No	921	93.0
Yes, with no cardiac or joint involvement	33	3.3
Yes, with cardiac involvement§	23	2.3
Yes, with joint involvement	11	1.1
Yes, with cardiac and joint involvement§	2	0.2
Tocilizumab administration to treat MIS-C	8	0.8
Current status		
All symptoms resolved	969	97.9
Dead¶	8	0.8
Still symptomatic	7	0.7
Long-term sequelae	6	0.6
Center		
Peru	383	38.7
Costa Rica	299	30.2
Argentina	253	25.6
Colombia	43	4.3
Mexico	12	1.2

437 **Table 1.** Characteristics of the study sample ( $n = 990$ ).

438 \*45 cases of interstitial disease, 30 cases of consolidation, 4 cases of pleural effusion and 13 unspecified  
439 diagnoses.

440 †3 cases of interstitial disease, 3 cases of consolidation and 10 unspecified diagnoses.

441 ‡8 mycoplasmas, 3 rhinoviruses, 1 cytomegalovirus, 1 Epstein–Barr virus and 1 unspecified virus.

442 §10 cases of pericardial effusion, 6 cases of coronary dilatation, 5 cases of myocarditis and 4 cases of “other”  
443 cardiac involvement.

444 ¶Mean time from symptom onset to death was  $14 \pm 8$  days, ranging from 3 to 27.

445 *COVID-19*, coronavirus disease 2019; *PCR*, polymerase chain reaction; *SARS-CoV-2*, Severe acute  
446 respiratory syndrome coronavirus 2; *IgG*, immunoglobulin G; *BCG*, bacillus Calmette–Guérin; *ARDS*, Acute  
447 respiratory distress syndrome; *MIS-C*, multisystem inflammatory syndrome.


448

Characteristic	Odds ratio	P-value	95% confidence interval	
			Lower bound	Upper bound
Sex				
Male	Ref.			
Female	1.50	0.040	1.02	2.21
Age group				
0 y	Ref.			
1–2 y	0.63	0.118	0.35	1.13
3–5 y	0.82	0.556	0.43	1.58
6–11 y	1.13	0.670	0.65	1.98
12–17 y	0.92	0.821	0.47	1.82
Immunosuppressants, immunodeficiency or chemo				
No	Ref.			
Yes	1.65	0.451	0.45	6.05
Hospitalization				
No	Ref.			
Yes, without intensive care	6.87	<0.001	4.34	10.89
Yes, with intensive care	9.60	<0.001	2.77	33.27
Pyrexia ( $\geq 38.0/\geq 100.4$ °C/°F)				
No	Ref.			
Yes	1.84	0.011	1.15	2.96
Upper respiratory tract infection				
No	Ref.			
Yes	1.08	0.730	0.71	1.65
Diarrhea and/or vomiting				
No	Ref.			
Yes	1.05	0.822	0.67	1.64
Lower respiratory tract infection				
No	Ref.			
Yes	0.34	0.007	0.16	0.74
Headache				
No	Ref.			
Yes	0.88	0.746	0.42	1.87
Chest X-ray abnormalities (pneumonia and/or ARDS)				
No	Ref.			
Yes	4.40	<0.001	1.99	9.71
Oxygen support, mechanical ventilation and/or CPAP				
No	Ref.			
Yes	2.21	0.050	1.002	4.88
Administration of systemic corticosteroids				
No	Ref.			
Yes	4.39	<0.001	2.01	9.58
MIS-C diagnosis				
No	Ref.			
Yes, w/o cardiac involvement	10.35	0.050	1.005	>100
Yes, w/ cardiac involvement	45.48	0.011	2.44	>100
Center				
Hospital San Bartolomé (PE)	Ref.			
Hospital Nacional de Niños (CR)	0.58	0.034	0.34	0.96
Hospital Isidoro Iriarte (AR)	0.25	<0.001	0.14	0.46
Hospital Edgardo Rebagliati Martins (PE)	0.04	0.014	0.00	0.53
Hospital Pablo Tobón Uribe (CO)	0.05	<0.001	0.01	0.25
Clínica Jasmédica (PE)	1.48	0.466	0.51	4.28
Hospital General Regional 200 Tecámac (MX)	12.24	0.045	1.06	>100

449 **Table 2.** Multivariable logistic regression analysis of antibiotics use ( $n = 990$ ).

450 **FIGURES**


451 **Figure 1.** Reasons for antibiotic use ( $n = 243$ ).



452

453

454 **Figure 2.** Classes of antibiotics administered to the patients, alone or in combination ( $n = 243$ ).



455

456 *Notes:* cephalosporines include cefalexine, cefalotin, cefepime, cefotaxime, ceftazidime and ceftriaxone;  
457 aminoglycosides include amikacin and gentamicin; penicillins include amoxicillin and ampicillin;  
458 antianaerobic drugs include metronidazole; macrolides include azithromycin and clarithromycin;  
459 antistaphylococcal drugs include clindamycin, trimethoprim and vancomycin; carbapenems  
460 includemeropenem; others include various combinations of these antibiotics as well as fluoroquinolones  
461 (ciprofloxacin).

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478


479

480

481

482

483



484

485 **Figure 3.**Prevalence of antibiotic use between April and October 2020.

486 *Notes:* Linear trend was assessed using a linear regression model with variance-weighted least squares.

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502